agilon Health Faces Securities Suit Alleging Misdiagnosed Financial Forecasts

Agilon Health sold investors a confident story. Strong guidance. Strategic actions. A stronger foundation for growth. But that optimism did not last long.

In February 2025, agilon told the market it was on track for a solid year. Executives promised improved margins, controlled costs, and hundreds of thousands of Medicare Advantage members coming onto the platform.

Then in May, management doubled down. They said the company was still on track to hit its full-year guidance.

Behind the scenes, the lawsuit says industry headwinds were worsening and those so-called strategic fixes were not going to help until 2026.

The truth came out in August. The CEO stepped down. The company suspended its 2025 guidance. Losses mounted. Revenue fell. Medical margins turned negative.

Investors were stunned. The stock collapsed by about 50% in a single day.

Now, shareholders say they were misled. And more investors are joining the lawsuit.